SIMEPREVIR PLUS PEGINTERFERON/RIBAVIRIN COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF CHRONIC GENOTYPE 1 HEPATITIS C IN COLOMBIA

被引：1
|
作者：
Ariza, J. G. [1 ]
Taborda, A. [2 ]
Naciben, V [3 ]
Heibeck, M. [4 ]
Westerhout, K. Y. [5 ]
机构：
[1] Janssen, Bogota, Colombia
[2] Johnson & Johnson, Sao Paulo, SP, Brazil
[3] Janssen Pharmaceut, Sao Paulo, Brazil
[4] Pharmerit Int, Berlin, Germany
[5] Pharmerit Int, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.020
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN26
引用
收藏
页码：A872 / A872
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN COLOMBIA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Garay, O. U.
    McMullen, M.
    Rey Ares, L.
    Idrovo, V
    Prieto Ortiz, J.
    Tapias, M.
    Obregon, J.
    Ariza, J. G.
    Caporale, J.
    VALUE IN HEALTH, 2013, 16 (07) : A693 - A693
  • [22] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER 'REAL-LIFE' CONDITIONS
    Ruiz-Antoran, B.
    Sancho-Lopez, A.
    Payares, C.
    de la Revilla, J.
    Calleja Panero, J. L.
    Avendano-Sola, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 18 - 18
  • [23] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    Gea, F.
    Barcena, R.
    Larrubia, J.
    Perez Alvarez, R.
    Sousa, J.
    Romero-Gomez, Manuel
    Sola, R.
    de la Revilla, J.
    Crespo, J.
    Navarro, J.
    Arenas, J.
    Delgado, M.
    Fernandez Rodriguez, C.
    Planas, R.
    Buti, M.
    Forns, X.
    Calleja, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [24] Cost-effectiveness of peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
    Siebert, U
    Sroczynski, G
    Rossol, S
    Wasem, J
    Ravens-Sieberer, U
    Kurth, BM
    Manns, MP
    Hutchison, JG
    Wong, JB
    JOURNAL OF HEPATOLOGY, 2002, 36 : 129 - 130
  • [25] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    de la Revilla, J.
    Crespo, J.
    Salcedo de Diego, I.
    Payares, C.
    Forns, X.
    Calleja, J. L.
    Avendano-Sola, C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E154 - E154
  • [26] Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
    Manns, M. P.
    Fried, M. W.
    Zeuzem, S.
    Jacobson, I. M.
    Forns, X.
    Poordad, F.
    Peeters, M.
    Fu, M.
    Lenz, O.
    Ouwerkerk-Mahadevan, S.
    Jessner, W.
    Scott, J. A.
    Kalmeijer, R.
    De La Rosa, G.
    Sinha, R.
    Beumont-Mauviel, M.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (04) : 366 - 375
  • [27] Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
    Shiffman, Mitchell L.
    Salvatore, Jennifer
    Hubbard, Sarah
    Price, Angie
    Sterling, Richard K.
    Stravitz, R. Todd
    Luketic, Velituir A.
    Sanyal, Arun J.
    HEPATOLOGY, 2007, 46 (02) : 371 - 379
  • [28] Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1
    Ciaccio, Antonio
    Cortesi, Paolo
    Bellelli, Giuseppe
    Rota, Matteo
    Rota, Monica
    Mantovani, Lorenzo G.
    Annoni, Giorgio
    Strazzabosco, Mario
    HEPATOLOGY, 2015, 62 : 919A - 919A
  • [29] Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
    Cure, Sandrine
    Guerra, Ines
    Camma, Calogero
    Craxi, Antonio
    Carosi, Giampiero
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (09) : 678 - 690
  • [30] A cost utility analysis of simeprevir used with peginterferon plus ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service
    Westerhout, Kirsten
    Treur, Maarten
    Mehnert, Angelika
    Pascoe, Katie
    Ladha, Imran
    Belsey, Jonathan
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 838 - 849
12345